Evolutionary profile of patients with hemoglobin SC disease regularly followed in Côte d'Ivoire

N'dogomo Méité, Clotaire D. Nanho, Mahawa Sangaré, Boidy Kouakou, Ismael Kamara, Alexis D. Silué, Saint-cyr Packo, Renée P. Botti, Emeraude N’dahtz, Gustave K. Koffi, Ibrahima Sanogo


Background: West Africa is recognized as the elective focus of hemoglobin C. The S and C combination in the same patient gives a major sickle cell syndrome. In our country, very few series dealing with the evolutionary features of this SC form have been published contrary to the homozygous SS form. The aim of this study was to describe the evolutionary profile of double heterozygous SC sickle cell patients.

Methods: This was a retrospective and prospective study with descriptive and analytical purpose of 174 SC sickle cell patients.

Results: The median age was 26 years with extremes of 6 years and 57 years. 96% of patients had less than 4 vaso-occlusive seizures per year. The evolutionary complications were mainly ischemic (56.30%) and infectious (39.10%). Among ischemic complications, sickle cell retinopathies and aseptic osteonecrosis are the most common with 59.20% and 31.63% respectively. Infectious complications were dominated by ENT (36.76%) and osteoarticular (35.29%) infections. Only age had an influence on the occurrence of ischemic complications (p = 0.0001). The probability of survival at 5 years was 99.38% and that at 20 years was 91.57%. The overall survival was not influenced by evolutionary complications.

Conclusions: Infectious and ischemic evolutionary complications show the importance of vaccination and an early screening program.


Complication, Hemoglobin S disease, Hemoglobin C disease, Hemoglobin SC disease, Mortality, Prevention

Full Text:



Itano HA, Neel JV. A new inherited abnormality of human hemoglobin. Proceedings Nation Acad Sci. 1950;36(11):613-7.

Cabannes R. Epidemiology of sickle cell disease. Ann Univ Abidjan. 1976;10:77-98.

Livingstone FB, Livingstone FB. Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants, and ovalocytosis in human populations. Oxford Uni Press, USA. 1985:478-512.

Diop S, Mokono SO, Ndiaye M, Touré Fall AO, Thiam D, Diakhaté L. Homozygous sickle cell disease in patients above 20 years of age: follow-up of 108 patients in Dakar. Rev Med Interne. 2003 Nov;24(11):711-5.

Tolo-Diebkilé A, Koffi KG, Nanho DC, Sawadogo D, Kouakou B, Siransy-Bogui L, et al. Homozygous sickle cell disease in Ivory Coast adults. Sante (Montrouge, France). 2010;20(2):63-7.

RGPH 2014, General Census of Population and Housing, 2014. Available at: Accessed 22 October 2018.

Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four‐decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70:206-15.

Lionnet F, Hammoudi N, Stojanovic KS, Avellino V, Grateau G, Girot R, et al. Hemoglobin SC disease complications: a clinical study of 179 cases. Haematol. 2012.

Berthet S, Monpoux F, Soummer AM, Bérard E, Sarles J, Badens C. Neonatal screening for sickle cell disease at the University Hospital of Nice: a review of the last 8 years. Pediatr Arch. 2010 Dec 1;17(12):1652-6.

Rahimy MC. Early detection and medical management of sickle cell anemia: five years of experience in Cotonou. Pediatr Arch. 1999;6:343s.

Connes P, Alexy T, Detterich J, Romana M, Hardy-Dessources MD, Ballas SK. The role of blood rheology in sickle cell disease. Blood Rev. 2016;30(2):111-8.

Tripette J, Alexy T, Hardy-Dessources MD, Mougenel D, Beltan E, Chalabi T, et al. Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease. Haematol. 2009;94:1060-5.

Al-Hawsawi ZM, Islam MS, Shehata NS. Sickle cell hemoglobin C disease in Saudi Arabia. Saudi Med J. 2003;24(2):209-12.

Gualandro SF, Fonseca GH, Yokomizo IK, Gualandro DM, Suganuma LM. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. Brit J Haematol. 2015;171(4):631-7.

Sangaré A. Sickle cell pain. J Panafr Pain. 1995; 1-12.

Latoundji S, Anani L, Ablet E, Zohoun I. Morbidity and sickle cell death in Benin. Med Afr Noire. 1991;38:5716.